

# Comparaison des tendances d'utilisation des antipsychotiques en France et aux USA

A Gallini, HA Huskamp, JM Donohue

# Contexte

- Arrivée sur le marché de nouveaux AP (seconde génération)
  - Moins d'EI de type dyskinésie
  - Supposés plus efficaces que les mol. de 1ère génération
- Nouvelles informations
  - Sécurité
    - Risque métabolique sous olanzapine (2003)
    - Risque accru de décès chez patient dément (2005-2008)
  - Effectivité
    - Publication des essais CATIE et CutLASS

# Objectifs

- Décrire et comparer entre France et USA les tendances d'utilisation d'antipsychotiques
  - L'adoption des nouvelles molécules
  - La réponse aux nouvelles informations

# Médicaments disponibles

- 1<sup>ère</sup> génération (formes orales)
  - 22 disponibles en France vs. 11 aux USA
  - 4 en commun (chlorpromazine, haloperidol, pimozide et loxapine)
- 2<sup>ème</sup> génération
  - 5 disponibles en France vs. 7 aux USA
  - Commercialisation française env.2.5 ans après US
  - Indications différentes

	USA		France		
	Approval date	Indications	Approval date	Marketing date	Indications
Paliperidone	Dec 2006	- Schizophrenia	Jun 2007*	-	
Aripiprazole	Nov 2002 Sep 2003 Sep 2004 Mar 2005 Nov 2007 Nov 2009	- Schizophrenia - Maintenance treatment in schizophrenia - Acute treatment of manic or <i>mixed</i> episodes in bipolar I disorder - Preventive treatment in bipolar I disorder - <i>Adjunctive treatment of major depressive disorder</i> - <i>Irritability associated with autistic disorder</i> - <i>Agitation associated with schizophrenia or bipolar mania</i>	Jun 2004 Mar 2008 Mar 2008	Jun 2004	- Schizophrenia - Acute treatment of manic episodes in bipolar disorder - Maintenance treatment in bipolar disorder
Ziprasidone	Feb 2001 Jun 2002 Aug 2004	-Schizophrenia - Acute agitation in schizophrenic patients -Acute treatment of manic or mixed episodes in bipolar I disorder - Maintenance treatment in bipolar I disorder (adjunct treatment)	-	-	Special authorization (ATU) since 2007
Quetiapine	Sep 1997 Jan 2004 Jan 2004 Jan 2004	- Schizophrenia - Acute treatment of manic episodes in bipolar I disorder - Acute treatment of depressive episodes in bipolar disorder - Maintenance treatment in bipolar I disorder	Nov 2010 Nov 2010 Nov 2010 Nov 2010 Nov 2010	Oct 2011	- Schizophrenia - Acute treatment of manic episodes in bipolar disorder - Acute treatment of depressive episodes in bipolar disorder - Maintenance treatment in bipolar disorder - <i>Adjunctive treatment of major depressive disorder</i>
Olanzapine	Sep 1996 Mar 2000 Dec 2003 Jan 2007 Mar 2009	- Schizophrenia - Acute treatment of manic or <i>mixed</i> episodes in bipolar I disorder ( <i>in combination</i> Jul 2003) - <i>Depressive episodes associated with bipolar I disorder with fluoxetine</i> - Schizophrenia or acute manic or mixed episodes in BP in children 13-17 yo - Maintenance treatment in bipolar I disorder - <i>Add-on treatment in severe depression (with fluoxetine)</i>	Sep 1996 Jun 2002 Oct 2003	Jun 1999	- Schizophrenia - Acute treatment of manic episodes in bipolar disorder - Maintenance treatment in bipolar I disorder
Risperidone	Dec 1993 Mar 2002 Dec 2003 Aug 2007 Oct 2006	- Schizophrenia - Maintenance treatment in schizophrenia - Acute treatment of manic or <i>mixed</i> episodes in bipolar I disorder in monotherapy or in combination - Schizophrenia and BP in children 13-17 yo - Irritability associated with autistic disorder in children	May 1995 Aug 2006 Aug 2006 Aug 2006	Feb 1996	- Schizophrenia - Acute treatment of manic episodes in bipolar disorder - Aggressiveness in children with mental retardation (short-term, precautions) - <i>Aggressiveness in AD patients (short-term, last line)</i>
Clozapine	Sep 1989	- Treatment resistant schizophrenia	Jun 1991	Jun 1997	- Treatment resistant schizophrenia - <i>Psychotic disorders in Parkinson's disease</i>
Amisulpride	-	-	Jan 1986	Mar 1991	- Schizophrenia

# Matériels et méthodes

- Sources de données
  - France: données de vente - base GERS
  - USA: prescriptions d'un échantillon représentatif de médecins
- Unité utilisée
  - Nombre de traitements mensuels pour 1000 habitants
- Période: janvier 1998 – septembre 2008
- Formes orales d'antipsychotiques

# Résultats (1)




Figure 1. Trends in total antipsychotic, FGA and SGA use in the USA and in France

# Résultats (2)






Figure 2. Evolution of FGA and SGA market shares in the USA and in France



# Résultats (3)



# Résultats (4)



# Pistes de discussion

- Adoption des nouvelles molécules
  - Malgré les différentiels de coût pour le patient aux USA
  - Différences culturelles
- Evolution des prescriptions
  - Stabilité des tendances en France vs. variations aux USA
  - Diffusion des informations
  - Aversion au risque